Jun 2026 (Q2 FY26) — Aug 5, 2026
Lifecore Biomedical Q2 FY26 — Strong Business Development Momentum and Reaffirmed Guidance
Read the full callLifecore Biomedical (LFCR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- May 2025
Lifecore Biomedical earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 34.2 | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. No quarter a year earlier is in the series, so no change is shown. | |
| Operating margin | 7.5 | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. No quarter a year earlier is in the series, so no change is shown. | |
| Net profit | -6.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. No quarter a year earlier is in the series, so no change is shown. |
Price
$6.39 +0.16% · +$0.01
Performance −1.5% 1Y
1Y: $6.49 on 17 Oct 2025 → $6.39. High $8.82 (26 Jan 2026), low $3.66 (27 Mar 2026).
- Previous close
- $6.38
- 52-week range
- $3.66 – $8.82
- One year
- −3.62%
Overview
- Symbol
- LFCR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Lifecore Biomedical earnings calls (LFCR)
Financials
What the filings say
Net profit, against the quarter before: +59% (quarter to jun 2026 against mar 2026).
| Line item | May 2024 | Aug 2024 | Nov 2024 | Feb 2025 | May 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 38 | 25 | 33 | 35 | 36 | 31 | 23 | 34 |
| Operating profit | 2 | -12 | -2 | -9 | 5 | -3 | -5 | 3 |
| Operating margin | 5.7% | −46.9% | −6.0% | −25.7% | 14.6% | −9.9% | −20.1% | 7.5% |
| Profit before tax | -7 | -16 | -7 | -15 | -1 | -10 | -15 | -6 |
| Tax rate | 0.8% | 0.1% | −0.7% | 0.1% | −3.0% | −3.5% | −0.3% | −0.4% |
| Net profit | -7 | -16 | -7 | -15 | -1 | -10 | -15 | -6 |
| EPS ($ per share) | — | -0.53 | -0.25 | -0.42 | -0.06 | -0.29 | -0.43 | -0.19 |
| Line item | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 109 | 110 | 71 | 38 | -79 | -179 | -167 | -205 |
| Total liabilities | 152 | 249 | 310 | 300 | 187 | 218 | 200 | 192 |
| Fixed assets | 160 | 200 | 192 | 107 | 119 | 134 | 149 | 129 |
| Total assets | 405 | 519 | 294 | 502 | 275 | 254 | 254 | 239 |
| Line item | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 20 | 16 | -17 | 16 | -23 | -17 | 0 | -0 |
| Cash from investing | -36 | -97 | -24 | -12 | 80 | -5 | -18 | -6 |
| Cash from financing | 13 | 79 | 40 | -3 | -57 | 40 | 8 | 6 |
| Net cash flow | -3 | -2 | -1 | 1 | 0 | 17 | -11 | -0 |
| Capital expenditure | -34 | -45 | -12 | -19 | -26 | — | -18 | -13 |
| Free cash flow | -14 | -29 | -29 | -3 | -49 | — | -18 | -14 |
Insider filings
11 filings between Mar 2, 2026 and Jun 4, 2026.
Open market
decisions to buy or sellNobody bought or sold LFCR on the open market in this window. The filings below are 9 awards and 2 tax withholdings.
Compensation
not trading decisions- 9
- Award — granted as compensation
- 2
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 4, 2026 | Kiper Christopher S Director | Award | 25,907 | — |
| Jun 4, 2026 | HOUDE LOVAS KATRINA Director | Award | 25,907 | — |
| Jun 4, 2026 | Schechter Joshua Director | Award | 25,907 | — |
| Jun 4, 2026 | Aryeh Jason Director | Award | 25,907 | — |
| Jun 4, 2026 | Korenberg Matthew E Director | Award | 25,907 | — |
| Jun 4, 2026 | Antunes Humberto Calheiros Director | Award | 25,907 | — |
| Jun 4, 2026 | Johnson Paul Harold Director | Award | 25,907 | — |
| Jun 4, 2026 | OBUS NELSON Director | Award | 25,907 | — |
| May 20, 2026 | Josephs Paul Chief Executive Officer | Tax withheld | 40,413 | $184.7K |
| Apr 14, 2026 | Salus Thomas D. Chief Legal & Administration | Tax withheld | 24,645 | $128.2K |
| Mar 2, 2026 | Salus Thomas D. Chief Legal & Administration | Award | 30,000 | — |
| Sep 3, 2025 | Lake Ryan David Chief Financial Officer | Tax withheld | 22,932 | $176.8K |
| Jul 15, 2025 | Kiper Christopher S Director | Award | 19,506 | — |
| Jul 15, 2025 | HOUDE LOVAS KATRINA Director | Award | 19,506 | — |
| Jul 15, 2025 | Schechter Joshua Director | Award | 19,506 | — |
| Jul 15, 2025 | Antunes Humberto Calheiros Director | Award | 19,506 | — |
| Jul 15, 2025 | Korenberg Matthew E Director | Award | 19,506 | — |
| Jul 15, 2025 | Aryeh Jason Director | Award | 19,506 | — |
| Jul 15, 2025 | Johnson Paul Harold Director | Award | 19,506 | — |
| Jul 15, 2025 | OBUS NELSON Director | Award | 19,506 | — |
| Jul 8, 2025 | Salus Thomas D. Chief Legal & Administration | Tax withheld | 11,022 | $90.3K |
| Jul 8, 2025 | Josephs Paul Chief Executive Officer | Option exercise | 150,000 | — |
| Jul 8, 2025 | Josephs Paul Chief Executive Officer | Tax withheld | 54,857 | $449.3K |
| Jul 8, 2025 | Lake Ryan David Chief Financial Officer | Option exercise | 75,000 | — |
| Jul 8, 2025 | Lake Ryan David Chief Financial Officer | Tax withheld | 32,806 | $268.7K |
| Jul 8, 2025 | Salus Thomas D. Chief Legal & Administration | Option exercise | 37,000 | — |
| May 28, 2025 | English Aron R. 10% owner | Sale | 150,419 | $1.07M |
| May 27, 2025 | English Aron R. 10% owner | Sale | 1,139,504 | $7.41M |
| May 23, 2025 | English Aron R. 10% owner | Sale | 96,137 | $649.4K |
| May 20, 2025 | Josephs Paul Chief Executive Officer | Tax withheld | 21,532 | $142.8K |
| May 12, 2025 | English Aron R. 10% owner | Sale | 45,698 | $321.4K |
| May 9, 2025 | English Aron R. 10% owner | Sale | 700 | $4.9K |
| May 8, 2025 | English Aron R. 10% owner | Sale | 5,098 | $35.7K |
| May 7, 2025 | English Aron R. 10% owner | Sale | 15,847 | $111.1K |
| May 6, 2025 | English Aron R. 10% owner | Sale | 701 | $4.9K |
| May 5, 2025 | English Aron R. 10% owner | Sale | 24,543 | $173.8K |
| Apr 14, 2025 | Salus Thomas D. Chief Legal & Administration | Award | 45,000 | — |
| Apr 14, 2025 | Salus Thomas D. Chief Legal & Administration | Award | 170,000 | — |
| Jan 8, 2025 | Josephs Paul Chief Executive Officer | Purchase | 17,000 | $97.6K |
| Dec 6, 2024 | Lake Ryan David Chief Financial Officer | Award | 19,720 | $0 |
| Dec 6, 2024 | Lake Ryan David Chief Financial Officer | Tax withheld | 5,653 | $40.4K |
| Dec 6, 2024 | Josephs Paul Chief Executive Officer | Award | 38,461 | $0 |
| Dec 6, 2024 | Josephs Paul Chief Executive Officer | Tax withheld | 11,769 | $84.1K |
| Oct 7, 2024 | Lake Ryan David Chief Financial Officer | Option exercise | 75,000 | — |
| Oct 7, 2024 | Lake Ryan David Chief Financial Officer | Tax withheld | 34,138 | $173.8K |
| Oct 3, 2024 | Kiper Christopher S Director | Purchase | 1,311,312 | $5.38M |
| Oct 3, 2024 | Kiper Christopher S Director | Purchase | 152,102 | $623.6K |
| Oct 3, 2024 | WYNNEFIELD PARTNERS SMALL CAP VALUE LP I 10% owner | Purchase | 122,930 | $504.0K |
| Oct 3, 2024 | WYNNEFIELD PARTNERS SMALL CAP VALUE LP I 10% owner | Purchase | 169,753 | $696.0K |
| Sep 3, 2024 | Lake Ryan David Chief Financial Officer | Award | 262,500 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for LIFECORE BIOMEDICAL, INC. \DE\
Free account. Everything above stays public.
Write why you follow LIFECORE BIOMEDICAL, INC. \DE\ and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading